Long follow-up adds information about sustained exposure. It does not make an open-label comparison equivalent to the earlier randomized phase. Primary report
Study snapshot
Ten participants with Barth syndrome entered the TAZPOWER extension, and eight reached week 168. Safety and tolerability were primary extension outcomes. The report described improved walking distance, fatigue scores, and cardiac measurements relative to extension baseline. Injection-site reactions were the most common adverse events. Primary report
Our appraisal: identify the baseline before reading the change
A change from extension baseline is not necessarily the same quantity as a change from the original trial baseline. These reference points can reflect different prior exposure and participant selection. Any numerical summary should state which baseline it uses.
Duration and causal strength are also separate dimensions. Following a small cohort for years can reveal patterns not visible over weeks, but it still lacks the same-period untreated comparison needed to isolate treatment from other changes.
For a rare disorder, recruitment constraints are real. They explain why a study may be small; they do not eliminate uncertainty. Individual trajectories, concurrent care, missing observations, and the reasons two participants did not reach the final visit remain important.
This publication belongs to the same TAZPOWER evidence family as the parent and earlier extension reports. It should be linked as longer follow-up, not counted as another independent replication. A full assessment should consider the entire development program and current product-specific regulatory information separately. This page evaluates the study design and does not make a current regulatory-status claim.
Frequently asked questions
Was the 168-week extension randomized against ongoing placebo?
No. It was open label.
How many participants reached the final visit?
Eight of the ten who entered the extension.
Which baseline matters for reported changes?
The paper's specified extension baseline.
Does longer follow-up remove confounding?
No.
Is this independent replication of TAZPOWER?
No. It follows the same study program's participants.
Do rare-disease constraints eliminate uncertainty?
No. They contextualize the design but do not erase its limitations.
What should review prioritize?
Individual follow-up, baseline definitions, concurrent care, missing data, and safety reporting.